Rituximab Little Use in Resistant Idiopathic Nephrotic Syndrome Doctors Lounge The anti-CD20 monoclonal antibody, rituximab, added to prednisone and calcineurin inhibitors, does not provide any additional benefit in terms of reduced proteinuria in the treatment of children with resistant idiopathic nephrotic syndrome, ... |
